FDA & Product Rules

FDA Warning Letter Flags Empower Pharmacy Compounded GLP-1 Telehealth Menus

FDA's September 18, 2026 warning letter to Empower Pharmacy ties high-volume compounded GLP-1 combinations to telehealth-style menus that preselect significant-difference language under section 503A.

E-commerce 4 Internet Marketers Editorial

Illustration of a late-September Northeastern U.S. community town green at golden hour, with a wooden health-fair booth, clipboard stack, and two colleagues talking beside a cork board of blank seasonal flyers.

By E-commerce 4 Internet Marketers Editorial

The U.S. Food and Drug Administration (FDA) issued a warning letter dated September 18, 2026, to Empower Clinic Services, LLC, doing business as Empower Pharmacy, after a November 2025 inspection of the Houston facility. Investigators concluded that compounded semaglutide and tirzepatide combination products appeared to be essentially copies of commercially available drugs produced regularly and in inordinate amounts, and that telehealth-style prescription workflows with preselected menu options undermined individualized significant-difference determinations under section 503A of the Federal Food, Drug, and Cosmetic Act (FD&C Act).

The letter (MARCS-CMS 738238) is addressed to founder and chief executive officer Arta Shaun Noorian. It matters immediately for online pharmacy and telehealth operators that separate consult checkout from pharmacy fulfillment. Product menus, marketing claims, and pharmacy partner contracts that present compounded glucagon-like peptide-1 (GLP-1) SKUs as commodity substitutes for branded products raise both FDA and card-processor risk.

What the September 18 letter says

FDA investigators inspected Empower’s Houston site at 7601 N. Sam Houston Pkwy W., Ste. 100, from November 3 through November 14, 2025, and issued a Form FDA 483 on November 14, 2025. The agency says it reviewed facility responses dated December 8, 2025, March 18, 2026, and April 30, 2026.

Section 503A of the FD&C Act sets conditions under which compounded human drugs can qualify for exemptions from current good manufacturing practice (CGMP), adequate-directions-for-use labeling, and FDA approval before marketing. One condition is that compounders must not regularly, or in inordinate amounts, produce drug products that are essentially copies of commercially available drugs. A compounded product is not treated as essentially a copy when a change made for an identified individual patient produces a significant difference for that patient, as determined by the prescribing practitioner.

FDA states that Empower compounded products including tirzepatide/niacinamide and semaglutide/cyanocobalamin formulations that appear to be essentially copies of FDA-approved semaglutide and tirzepatide products. The letter cites high monthly order volumes from July through October 2025 for three named combination products (specific counts are redacted as (b)(4) in the published letter). FDA writes that the volume of products produced “suggests that differences between products you are compounding and the FDA-approved products are pretextual.”

A footnote reminds readers that FDA previously exercised enforcement discretion for certain compounded semaglutide and tirzepatide injection products during shortage periods, and that the discretion period ended for tirzepatide injection products on March 5, 2025, and for semaglutide injection products on April 24, 2025.

Preselected menus and significant-difference documentation

Beyond volume, the letter focuses on how “significant difference” determinations were recorded. Evidence cited includes:

  1. Orders and prescriptions that lack any prescriber determination of significant difference from the commercially available product.
  2. Orders and prescriptions with purported significant-difference language that appears repeated verbatim across many records, suggesting pre-generated text selected by the prescriber rather than written for an identified individual patient.
  3. The volume of particular products compounded and orders filled.

FDA states that generating prescriptions through means that undermine individualized clinical judgment, “for example through third-party technology platforms that provide prescribers with pre-selected menu options for choosing a statement of significant difference,” calls those determinations into question and may undermine claims that they satisfy section 503A conditions.

For telehealth and online pharmacy stacks, that sentence is the operational core. Checkout flows, clinician portals, and pharmacy partner APIs that offer drop-down or radio-button justifications for compounded GLP-1 combinations are now described in an FDA warning letter as a compliance risk when they replace patient-specific clinical writing.

Sterility, CGMP, and corrective-action gaps

The letter also alleges insanitary conditions and CGMP violations for products intended to be sterile, including inadequate smoke studies under dynamic conditions and media fills not performed under the most challenging conditions. CGMP citations include equipment systems for aseptic conditions, procedures to prevent microbiological contamination, quality-unit oversight, environmental monitoring, and production and process controls.

FDA reviewed Empower’s Form 483 responses and said some corrective actions appear inadequate or insufficiently documented. Examples include a smoke study that remained in post-execution review without a finalized summary provided to FDA, media-fill vial-count discrepancies between summary reports and underlying records, undefined “N/A” labels on records, and media-fill results transcribed onto a different form revision without a clear audit trail.

Products that do not meet section 503A conditions are treated in the letter as ineligible for those exemptions. FDA alleges the ineligible products are unapproved new drugs and misbranded for lacking adequate directions for use, and that introducing them into interstate commerce can violate the Act. The firm was given fifteen working days from receipt to respond in writing.

Industry reaction and Empower’s public statement

Legal analysts at Frier Levitt, writing on September 25, 2026, described the letter as signaling a sharper enforcement theory for compounded GLP-1 combination products. They note FDA’s use of “pretextual” in this setting, the agency’s attention to templated significant-difference language and third-party prescribing platforms, and the April 1, 2026 GLP-1 compounding policy update that used a semaglutide-plus-vitamin-B12 example when discussing essentially-a-copy analysis.

CBS News reported on September 24, 2026, that the warning letter was posted online that week and quoted Empower saying it has “already remediated many of the issues outlined in the Warning Letter” and will “continue to work cooperatively with the agency to ensure patient access to quality compounded drug products.” CBS also noted ongoing private litigation, including claims by Eli Lilly that marketing of personalized compounded products can be deceptive when standardized copies are produced at scale. Those civil claims remain separate from the FDA letter and are unresolved in the reporting cited here.

Why telehealth checkout and pharmacy partners should scrub menus now

Website owners and developers who run telehealth consult funnels into compounding pharmacies often treat SKU names, vitamin add-ons, and “significant difference” checkboxes as conversion details. The Empower letter treats those same design choices as evidence when volume and identical wording stack up.

Practical implications for operators who keep consult payment separate from pharmacy fulfillment include:

  • Audit every clinician-facing menu that auto-inserts significant-difference language for compounded semaglutide or tirzepatide combinations.
  • Align product descriptors and catalog copy with what pharmacy partners actually document for individual patients, not with commodity weight-loss marketing.
  • Review contracts so marketing claims, fulfillment volumes, and documentation duties match section 503A expectations after the 2025 end of shortage enforcement discretion.
  • Expect processors and underwriters reviewing telemedicine acquiring files to ask how compounded GLP-1 SKUs are described on the storefront and on statements after an FDA letter that ties menu design to pretext findings, which is why specialty teams sometimes consult Organic Payment Gateways for telemedicine-friendly acquiring options while rebuilding those packets.

None of that substitutes for counsel. The letter is agency enforcement against one named pharmacy, not a new statute. It does show how FDA is reading volume, combination formulations, and technology-assisted prescribing menus together.

Closing

FDA’s September 18, 2026 warning letter to Empower Pharmacy links high-volume compounded semaglutide and tirzepatide combination production with prescription records that either omit significant-difference determinations or recycle identical menu-ready language. Telehealth and online pharmacy operators that still ship patients through preselected justification workflows should treat menu design, marketing copy, and pharmacy documentation as one compliance surface, not three disconnected vendor tasks, before the next inspection or underwriting review asks the same questions FDA put on paper.

Sources